Celsius Therapeutics Launches with $65 Million Series A to Develop Autoimmune and Cancer Precision Therapies

Celsius Therapeutics, launched on 5/15/18 with a $65 million Series A financing led by Third Rock Ventures with participation from GV (formerly Google Ventures), Heritage Provider Network, Casdin Capital, Alexandria Venture Investments and other key investors. Celsius is charting a new course of target and drug discovery by understanding the specific cells, among many others, that are key players in disease and by identifying the genes that are triggering their malfunction.